Search

Search Results

• 

  New approved drugs for psoriatic arthritis

  F.M. Perrotta, E. Lubrano

  57-64

  09-09-2016

  https://doi.org/10.4081/reumatismo.2016.873

  3295

  PDF: 2290
• 

  Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab

  Ebru Atalar, Hatice Ecem Konak, Pınar Akyüz Dağlı, Bahar Özdemir Ulusoy, Özlem Karakaş, Kevser Orhan, Rezan Koçak Ulucaköy, Esra Kayacan Erdoğan, Serdar Can Güven, Orhan Küçükşahin, İsmail Doğan, Hakan Babaoğlu, Yüksel Maraş, Şükran Erten, Ahmet Omma, Berkan Armağan

  26-06-2025

  https://doi.org/10.4081/reumatismo.2025.1792

  1940

  PDF: 130
• 

  Effects of secukinumab on serum adipocytokines: preliminary data

  A. Fassio, D. Gatti, P. Gisondi, G. Girolomoni, O. Viapiana, A. Giollo, M. Zamboni, M. Rossini, L. Idolazzi

  105-110

  21-09-2017

  https://doi.org/10.4081/reumatismo.2017.953

  2934

  PDF: 1557
• 

  Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

  G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini, A. Fassio

  08-05-2023

  https://doi.org/10.4081/reumatismo.2023.1559

  1912

  PDF: 1025
• 

  Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review

  Eleonora Celletti, Giulio Gualdi, Emanuela Sabatini, Francesco Cipollone, Fabio Lobefaro, Paolo Amerio

  27-01-2025

  https://doi.org/10.4081/reumatismo.2025.1694

  2236

  PDF: 255

• PO:02:018 | After-SECs: clinical predictors of secukinumab retention in psoriatic arthritis patients with inadequate response to anti-tumor necrosis factor therapy Francesco Cristiano¹, Davide Gaspare Patti¹, Valentina Boni¹, Stefano Di Murro¹, Cesare Gavotti¹, Roberta Masnata¹, Giulia Calabrese², Gerlando Natalello², Giusy Peluso², Augusta Ortolan^1|2, Enrico De Lorenzis^1|2, Maria Antonietta D'Agostino^1|2. | ¹Università Cattolica del Sacro Cuore, Roma, Italy; ²Divisione di Reumatologia ed Immunologia clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2009

  81

• PO:01:004 | Real-world retention of IL-17 inhibitors in psoriatic arthritis: impact of prior IL-17 exposure across multiple treatment lines in the “BIRRA” multicentre cohort Valentino Paci¹, Alarico Ariani², Eleonora Celletti³, Alberto Lo Gullo⁴, Camilla Mazzanti⁵, Valeria Nucera⁶, Natalia Mansueto⁷, Rosalba Caccavale⁸, Patrizia Del Medico⁹, Antonella Farina¹⁰, Palma Scolieri¹¹, Cecilia Giampietro¹², Olga Addimanda¹³, Riccardo Bixio¹⁴, Maddalena Larosa¹⁵, Viviana Ravagnani¹⁶, Federica Lumetti¹⁷, Aldo Biagio Molica Colella¹⁷, Elena Bravi¹⁷, Rosetta Vitetta¹⁷, Bernd Raffeiner¹⁷, Gilda Sandri¹⁸, Rosario Foti¹⁹, Simone Parisi²⁰, Michele Maria Luchetti Gentiloni¹, Gianluca Moroncini¹. | ¹Clinical Medicine, Department of Clinical and Molecular Sciences, Marche Polytechnic University, AOU delle Marche, Ancona, Italy; ²Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy; ³Rheumatology Unit, Clinica Medica Institute, Ospedale SS. Annunziata di Chieti, G.d'Annunzio University of Chieti, Chieti, Italy; ⁴Rheumatology Unit, ARNAS Garibaldi di Catania, Catania, Italy; ⁵Center for the Diagnosis and Therapy of Autoimmune Rheumagological Diseases, Ospedale Santa Rosa, ASL Viterbo Viterbo Italy; ⁶Rheumatology Outpatient Unit, ASL Novara, Novara, Italy; ⁷Ambulatori di Reumatologia ASL1 Liguria, Imperia Hospitall Imperia Italy; ⁸Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, Roma, Italy; ⁹Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche Hospital, Civitanova Marche, Italy; ¹⁰Internal Medicine Unit, Rheumatology outpatient clinic, Ospedale A. Murri di Fermo, Fermo, Italy; ¹¹Department of Medical Specialties, Nuovo Regina Margherita Hospital, Rome, Roma, Italy; ¹²Rheumatology Outpatient Clinic, Azienda ULSS 6 Euganea, Padova, Padova, Italy; ¹³Rheumatology Unit, Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- AOU di Bologna, Bologna, Italy; ¹⁴Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; ¹⁵Division of Rheumatology - Medical Specialties Department, Ospedale La Colletta-Azienda Sanitaria Locale 3, Genova, Italy; ¹⁶Rheumatology Unit, Santa Chiara Hospital APSS Trento Italy; ¹⁷BIRRA - BIologic Retention Rate in chronic Arthritis - study group, Parma, Italy; ¹⁸Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; ¹⁹Rheumatology Unit, Policlinico San Marco Hospital, Catania, Italy; ²⁰Rheumatology Department, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2001

  109
• 

  Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study

  F.M. Perrotta, A. Delle Sedie, S. Scriffignano, P. Volpe, E. Cordisco, N. Milano, M. Gabini, E. Lubrano

  52-59

  10-04-2020

  https://doi.org/10.4081/reumatismo.2020.1266

  2215

  PDF: 1247